Cover Image
市場調查報告書

免疫學相關的各種合作契約:契約條件・合意內容

Global Immunology Partnering 2010-2016: Deal trends, players and financials

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 250302
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
免疫學相關的各種合作契約:契約條件・合意內容 Global Immunology Partnering 2010-2016: Deal trends, players and financials
出版日期: 2016年09月01日 內容資訊: 英文
簡介

本報告,調查分析2007年以後免疫學相關的各種合作契約,彙整各種契約的近年動向、大型契約及大型醫藥品業者的契約概要、契約區分・開發階段・技術區分・適應症區分別的指南等,由下列摘要形式闡述。

報告摘要

第1章 簡介

第2章 免疫學相關的各種契約動向

  • 簡介
  • 過去數年免疫學相關的合作
  • 大型藥廠的契約活動
  • 對免疫學相關事業不積極的大型藥廠
  • 免疫學相關的合作:契約類型別
  • 免疫學相關的合作:產業部門別
  • 免疫學相關的合作:開發階段別
  • 免疫學相關的合作:技術類型別
  • 免疫學相關的合作:適應症別
  • 平均契約期間

第3章 主要契約

  • 簡介
  • 主要契約:交易額別
  • 大型藥廠涉及的主要契約

第4章 大型藥廠的契約

  • 簡介
  • 大型藥廠的合作契約利用法
  • 企業檔案資料

第5章 契約指南

  • 簡介
  • 契約類型別
    • 資產購買
    • 讓渡
    • 大型企業的委外授權
    • 共同開發
    • 共同R&D
    • 共同銷售
    • 服務契約
    • 共同推廣
    • 交叉授權
    • 銷售
    • 股票收購
    • 合資企業
    • 授權
    • 訴訟
    • 貸款
    • 製造
    • 市場行銷
    • 選項
    • 促銷
    • 研究
    • 合解相關
    • 資產分割
    • 再授權
    • 供給
    • 終了
  • 開發階段別
    • 藥物設計
    • 製劑
    • 第I階段
    • 第II階段
    • 第III階段
    • 前臨床
    • 法規
  • 技術類型別
    • 抗體
    • 分析
    • 生物學化合物
    • 細胞治療
    • 裝置
    • 藥物設計工具
    • 促成技術
    • 設備
    • 裝置
    • 基因體學
    • 體外模型
    • 天然產品
    • 寡核甘酸
    • 孤兒藥
    • 包裝
    • 胜肽
    • 加工
    • 蛋白質體學
    • 重組DNA
    • RNA治療
    • 篩檢
    • 小分子
    • 幹細胞
    • 疫苗

第6章 免疫學相關的契約:適應症別

  • 簡介
  • 適應症別
    • 免疫學
    • AIDS
    • 過敏症
    • 過敏性休克
    • 移植體對抗宿主疾病(GVHD)
    • 發炎
    • 全身紅斑性狼瘡(SLE)
    • 硬皮病

第7章 合作機會

  • 線上夥伴
  • 夥伴活動
  • 相關資料

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP2224

The ‘Global Immunology Partnering 2010-2016: Deal trends, players and financials report’ provides comprehensive understanding and unprecedented access to the immunology/autoimmune partnering deals and agreements entered into by the worlds leading healthcare companies

‘Global Immunology Partnering 2010 to 2016’ provides the full collection of Immunology disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

  • Trends in Immunology partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Immunology partnering agreement structure
  • Immunology partnering contract documents
  • Top Immunology deals by value
  • Most active Immunology dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Immunology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Immunology deals.

The report presents financial deal terms values for Immunology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Immunology dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Immunology dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Immunology deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Immunology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Immunology deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Immunology partnering deals by specific Immunology target announced since 2010. The chapter is organized by specific Immunology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Immunology partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Immunology partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Immunology technologies and products.

Report scope

‘Global Immunology Partnering 2010 to 2016’ is intended to provide the reader with an in-depth understanding and access to Immunology trends and structure of deals entered into by leading companies worldwide.

‘Global Immunology Partnering 2010 to 2016’ includes:

  • Trends in Immunology dealmaking in the biopharma industry since 2010
  • Analysis of Immunology deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Immunology deal contract documents
  • Comprehensive access to over 3500 Immunology deal records
  • The leading Immunology deals by value since 2010
  • Most active Immunology dealmakers since 2010

The report includes deals for the following indications: AIDS, Allergy, Anaphylactic shock, Graft versus host disease, Inflammation, Other autoimmune, Scleroderma, Systemic lupus erythematosus, plus other immunology indications.

In ‘Global Immunology Partnering 2010 to 2016’, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Immunology Partnering 2010-2016’ report provides comprehensive access to available deals and contract documents for over 700 immunology deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

‘Global Immunology Partnering 2010 to 2016’ provides the reader with the following key benefits:

  • In-depth understanding of Immunology deal trends since 2010
  • Access Immunology deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Immunology partner companies
  • Comprehensive access to over 750 links to actual Immunology deals entered into by the world's biopharma companies
  • Indepth review of Immunology deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Immunology opportunities
  • Uncover companies actively partnering Immunology opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Immunology dealmaking

  • 2.1. Introduction
  • 2.2. Immunology partnering over the years
  • 2.3. Immunology partnering by deal type
  • 2.4. Immunology partnering by industry sector
  • 2.5. Immunology partnering by stage of development
  • 2.6. Immunology partnering by technology type
  • 2.7. Immunology partnering by therapeutic indication

Chapter 3 -Financial deal terms for Immunology partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Immunology partnering
  • 3.3. Immunology partnering headline values
  • 3.4. Immunology deal upfront payments
  • 3.5. Immunology deal milestone payments
  • 3.6. Immunology royalty rates

Chapter 4 - Leading Immunology deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Immunology partnering
  • 4.3. List of most active dealmakers in Immunology
  • 4.4. Top Immunology deals by value

Chapter 5 - Immunology contract document directory

  • 5.1. Introduction
  • 5.2. Immunology partnering deals where contract document available

Chapter 6 - Immunology dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Immunology therapeutic target

Appendices

  • Appendix 1 - Directory of Immunology deals by company A-Z 2010 to 2016
  • Appendix 2 - Directory of Immunology deals by deal type 2010 to 2016
  • Appendix 3 - Directory of Immunology deals by stage of development 2010 to 2016
  • Appendix 4 - Directory of Immunology deals by technology type 2010 to 2016
  • Further reading on dealmaking
  • Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Immunology partnering since 2010
  • Figure 2: Immunology partnering by deal type since 2010
  • Figure 3: Immunology partnering by industry sector since 2010
  • Figure 4: Immunology partnering by stage of development since 2010
  • Figure 5: Immunology partnering by technology type since 2010
  • Figure 6: Immunology partnering by indication since 2010
  • Figure 7: Immunology deals with a headline value
  • Figure 8: Immunology deals with upfront payment values
  • Figure 9: Immunology deals with milestone payment
  • Figure 10: Immunology deals with royalty rates
  • Figure 11: Active Immunology dealmaking activity- 2010 to 2016
  • Figure 12: Top Immunology deals by value since 2010
Back to Top